PR Newswire·Nov 10, 2026, 4:00 PM ET

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals closed a $100 million strategic transaction with Apotex Health on July 1, 2026, integrating commercial brands into Apotex while focusing resources on its clinical pipeline.
The company announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
The NDA submission is supported by Phase 2 FIGHT DMD trial data showing a 5.4 percentage point improvement in left ventricular ejection fraction, along with a rolling review request granted by the FDA.
Ifetroban has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations, with the FDA conditionally accepting the proprietary name DYSCORBAN for this indication.
Top-line results from the Phase 2a ASSIST-SSc trial for systemic sclerosis showed ifetroban was well tolerated with no serious adverse events assessed as related to the study drug during the 12-month period.
Cumberland reported a net income of $77.8 million for the third quarter of 2026, driven by an $81.1 million gain on the divestiture of discontinued operations.
As of September 30, 2026, the company held $80.6 million in cash and cash equivalents with total assets of approximately $114 million.
The company is advancing a refined mission focused on innovation for rare diseases, with ifetroban as the lead candidate in late-stage development.